KeyBanc adjusted its price target for ResMed to $266 from $290 while maintaining an Overweight rating on the shares. The firm cited insights from the SLEEP APSS Meeting in Baltimore and further analysis of the obstructive sleep apnea competitive environment, which strengthened its confidence in ongoing patient demand trends. KeyBanc highlighted continued momentum in the OSA and CPAP markets, supported by increasing demand growth from factors such as GLP-1 adoption and consumer wearable technologies. Separately, ResMed completed its acquisition of Noctrix Health, a medical device company focused on wearable therapies for chronic neurological conditions, expanding its sleep health portfolio into Restless Legs Syndrome treatment.
ResMed IncKeyBanc maintained Overweight rating and adjusted price target to $266, citing strong demand trends and competitive environment.
Noctrix Health was acquired by ResMed, expanding its sleep health portfolio, but the company is private and not directly traded.